PRRX1 silencing is required for metastatic outgrowth in melanoma and is an independent prognostic of reduced survival in patients
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Josep R Ferreres und 12 weiteren Autor:innen. Beteiligte Einrichtung: TGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain. Hauptthemen laut MEDLINE: Melanoma, Homeodomain Proteins, Epithelial-Mesenchymal Transition, Neoplasm Metastasis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundació La Marató de TV3, Asociación Española Contra el Cáncer, AGAUR.
Abstract (Originalsprache)
Paired related homeobox 1 ( PRRX1 ) is an inducer of epithelial‐to‐mesenchymal transition (EMT) in different types of cancer cells. We detected low PRRX1 expression in nevus but increased levels in primary human melanoma and cell lines carrying the BRAF V600E mutation. High expression of PRRX1 correlates with invasiveness and enrichment of genes belonging to the EMT programme. Conversely, we found that loss of PRRX1 in metastatic samples is an independent prognostic predictor of poor survival for melanoma patients. Here, we show that stable depletion of PRRX1 improves the growth of melanoma xenografts and increases the number of distant spontaneous metastases, compared to controls. We provide evidence that loss of PRRX1 counteracts the EMT phenotype, impairing the expression of other EMT‐related transcription factors, causing dysregulation of the ERK and signal transducer and activator of transcription 3 (STAT3) signaling pathways, and abrogating the invasive and migratory properties of melanoma cells while triggering the up‐regulation of proliferative/melanocytic genes and the expression of the neural‐crest‐like markers nerve growth factor receptor (NGFR; also known as neurotrophin receptor p75NTR) and neural cell adhesion molecule L1 (L1CAM). Overall, our results indicate that loss of PRRX1 triggers a switch in the invasive programme, and cells de‐differentiate towards a neural crest stem cell (NCSC)‐like phenotype that accounts for the metastatic aggressiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- TGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
- Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), ISCIII, Instituto de Salud Carlos III, Madrid, Spain.
- Dermatology Service, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain.
- Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Germany.
- Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program (IDIBELL), Barcelona, Spain.
- Dermatology Department, Melanoma Unit, Hospital Clínic, IDIBAPS & University of Barcelona, Spain.
ORCID-Profile: Àngels Fabra
Förderung
- Fundació La Marató de TV3
- Asociación Española Contra el Cáncer
- AGAUR
- Instituto de Salud Carlos III (ISCIII)
- European Regional Development Fund
- Agència de Gestió d'Ajuts Universitaris i de Recerca
Zitieren
APA
Ferreres, J. R., Vinyals, A., Campos-Martin, R., Espín, R., Podlipnik, S., Ramos, R., Bertran, E., Carrera, C., Marcoval, J., Malvehy, J., Fabregat, I., Puig, S., & Fabra, À. (2024). PRRX1 silencing is required for metastatic outgrowth in melanoma and is an independent prognostic of reduced survival in patients. Molecular Oncology. https://doi.org/10.1002/1878-0261.13688
Vancouver
Ferreres JR, Vinyals A, Campos-Martin R, Espín R, Podlipnik S, Ramos R, et al. PRRX1 silencing is required for metastatic outgrowth in melanoma and is an independent prognostic of reduced survival in patients. Molecular Oncology. 2024. doi:10.1002/1878-0261.13688
BibTeX
@article{Ferreres2024,
author = {Ferreres, Josep R and Vinyals, Antònia and Campos-Martin, Rafael and Espín, Roderic and Podlipnik, Sebastian and Ramos, Raquel and Bertran, Esther and Carrera, Cristina and Marcoval, Joaquim and Malvehy, Josep and Fabregat, Isabel and Puig, Susana and Fabra, Àngels},
title = {PRRX1 silencing is required for metastatic outgrowth in melanoma and is an independent prognostic of reduced survival in patients},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13688}
}
EUVIMED